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Introduction: our study aimed to evaluate whether pathologic 
complete response (pCR) in early-stage non–small-cell lung cancer 
(NSCLC) after neoadjuvant chemotherapy resulted in improved out-
come, and to determine predictive factors for pCR.
Methods: Eligible patients with stage-IB or -II NSCLC were included 
in two consecutive Intergroupe Francophone de Cancérologie 
Thoracique phase-III trials evaluating platinum-based neoadjuvant 
chemotherapy, with pCR defined by the absence of viable cancer 
cells in the resected surgical specimen.
Results: Among the 492 patients analyzed, 41 (8.3%) achieved 
pCR. In the pCR group, 5-year overall survival was 80.0% com-
pared with 55.8% in the non-pCR group (p = 0.0007). In multivariate 
analyses, pCR was a favorable prognostic factor of overall survival 
(relative risk = 0.34; 95% confidence interval = 0.18–0.64) in addi-
tion to squamous-cell carcinoma, weight loss less than or equal 
to 5%, and stage-IB disease. Five-year disease-free survival was 
80.1% in the pCR group compared to 44.8% in the non-pCR group 
(p < 0.0001). Two patients (4.9%) in the pCR group experienced 
disease recurrence compared to 193 patients (42.8%) in the non-pCR 
group. SCC subtype was the only independent predictor of pCR 
(odds ratio [oR] = 4.30; 95% confidence interval = 1.90–9.72).
Conclusion: our results showed that pCR after preoperative chemother-
apy was a favorable prognostic factor in stage-IB–II NSCLC. our study 
is the largest published series evaluating pCRs after preoperative che-
motherapy. The only factor predictive of pCR was squamous-cell car-
cinoma. Identifying molecular predictive markers for pCR may help in 
distinguishing patients likely to benefit from neoadjuvant chemotherapy 
and in choosing the most adequate preoperative chemotherapy regimen.
Key Words: Pathologic complete response, Preoperative chemother-
apy, Neoadjuvant chemotherapy, Early-stage, Non–small-cell lung 
cancer.
(J Thorac Oncol. 2012;7: 841–849)
Treatment strategies combining chemotherapy and surgery have been developed to improve the survival of patients 
with early-stage non–small-cell lung cancer (NSCLC). Meta-
analyses of phase-III trials, particularly a recent one based on 
individual patient data, revealed a significant 5-year overall sur-
vival (oS) benefit of 5% when using preoperative chemotherapy 
in operable NSCLC.1–4 Similar to adjuvant chemotherapy, neo-
adjuvant chemotherapy aims to eradicate systemic micrometas-
tases and reduce the risk of recurrence especially in the case of 
distant metastases. one advantage of neoadjuvant chemother-
apy over adjuvant chemotherapy is that it allows for assessing 
tumor response and therefore tumor chemosensitivity.
Previous studies on breast and rectal cancers have dem-
onstrated that pathologic complete responses (pCR) after 
preoperative therapy were associated with improved oS and 
disease-free survival (DFS). Furthermore, pCR was consid-
ered to be a surrogate endpoint for long-term DFS.5–7
In NSCLC, responses and particularly mediastinal 
downstaging after preoperative chemotherapy or chemoradia-
tion were shown to be associated with improved survival.8–12 
However, there is little data on the prognostic value of pCR 
after preoperative chemotherapy.11,13–16 As pCR was shown 
not to exceed 17% after neoadjuvant chemotherapy, published 
reports on pCRs included only small series of patients.9,17–20 
In these studies, mainly involving stage-IIIA N2 NSCLC 
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patients, pCR after preoperative chemotherapy or chemo-
radiotherapy was shown to be a favorable prognostic factor. 
However, in these series, too few pCRs were observed to per-
mit a thorough analysis.
our study was based on the datasets from two con-
secutive French multicenter randomized phase-III trials from 
the Intergroupe Francophone de Cancérologie Thoracique 
(IFCT)9,21 on neoadjuvant chemotherapy, involving large 
series of patients with long-term follow-up. Because of the 
sufficiently high number of pCR observed in these two tri-
als, we were able to analyze the prognostic value of pCR, 
and determine positive predictors for pCR after neoadjuvant 
chemotherapy.
PATIENTS AND METHODS
Data Sources
The current analysis was performed using databases 
from two phase-III randomized trials evaluating neoadju-
vant chemotherapy: Depierre9 trial (trial I) and IFCT0002 
trial (trial II)21. In trial I undertaken between 1991 and 
1997, patients were randomized to either undergo immedi-
ate thoracic surgery or receive two cycles of chemother-
apy before surgery plus two further postsurgery cycles in 
responders, with chemotherapy consisting of mitomycin, 
ifosfamide, and cisplatin (MIC) combination (Fig. 1). 
In trial II undertaken between 2001 and 2006, two dif-
ferent chemotherapy strategies were compared: (1) two 
cycles before surgery plus two further presurgery cycles 
in responders (preoperative chemotherapy arms) and (2) 
two cycles before surgery plus two further postsurgery 
cycles in responders (perioperative chemotherapy arms). 
Chemotherapy comprised carboplatin-paclitaxel (CP) or 
gemcitabine-cisplatin (Fig. 2). Add itional details regarding 
the different treatment modalities were provided in pre-
vious publications.9,21 In both trials, eligible patients 
were aged between 18 and 75 years, with a World Health 
organization performance status (PS) less than or equal 
to 2, and histologically proven stage-IB, -IIA, or -IIB 
NSCLC. In addition, stage IIIA was included in trial I and 
stage IA in trial II. In both studies, initial staging investi-
gations involved chest radiograph, thoracic and abdomi-
nal computed-tomography (CT), fiberoptic bronchoscopy, 
and brain CT-scan or magnetic resonance imaging. In trial 
II, a mediastinoscopy was required before the randomiza-
tion of patients with mediastinal lymph nodes more than 
1 cm in their smallest diameter on CT-scan. Patients should 
undergo the same surgery they would have needed before 
neoadjuvant therapy, regardless of response. The follow-up 
procedures in the two trials included a physical examina-
tion and chest radiograph every 3 months, and a fiberop-
tic bronchoscopy and chest CT-scan every 6 months for 
the first 2 years. In trial I, from the third to the seventh 
year, follow-up consisted of a chest radiograph every 6 
months, and fiberoptic bronchoscopy and chest CT-scan 
every year. After 8 years, the investigators were invited to 
set up an annual clinic visit. In trial II, an annual follow-
up was scheduled to occur from the third to the fifth year 
involving a fiberoptic bronchoscopy and chest CT-scan, and 
thereafter a chest radiograph. Both trials were approved by 
the Human Investigations Committee of Franche-Comté, 
France. In total, 883 patients were included in the two ran-
domized trials, with median follow-up being 13.8 years 
(range: 10.4–16.6) in trial I and 5 years (range, 3.0–7.6) 
in trial II.
Study Population
In our analysis, only patients treated with preoperative 
chemotherapy followed by surgery were included. As stage 
IA patients were ineligible for trial I and stage IIIA patients 
for trial II, these patients were excluded from our analysis. 
Thus, only stage-IB and -II NSCLC patients were considered 
for our analysis (Fig. 3). All stages were redefined using the 
sixth tumor, node, metastasis, classification, which was used 
during trial II.22
FIGURE 1. Trial I design.
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Assessment of Response
Clinical response was assessed according to World 
Health organization criteria23 by means of chest CT-scan 
and fiberoptic bronchoscopy undertaken before surgery. 
Clinical complete response (cCR) was defined as the 
complete disappearance of all target lesions without any 
residual lesions. The absence of cancer cells in bronchial 
biopsy specimens was a requisite for cCR. Clinical partial 
response (cPR) was defined as more than 50% decrease 
in tumor mass, without progression of target lesions or 
appearance of new lesions. Stable disease was considered 
as less than 50% decrease or less than 25% increase in 
tumor mass without appearance of new lesions. Clinical 
progressive disease was defined as more than 25% 
increase in tumor mass or the appearance of new lesions. 
Last, pCR was defined as the absence of viable tumor 
detected in the resected surgical specimen on pathologic 
examination.
Statistical Methods
Differences in baseline patient characteristics accord-
ing to pathologic responses were assessed using chi-squared 
or Fisher’s exact tests. The primary objective was to compare 
postoperative oS according to pathologic responses. OS was 
defined as the time from surgery to any-cause death, date of 
last news, or date of trial endpoint. DFS was defined as the 
time from surgery to date of recurrence or date of death for 
patients who died without recurrence. In patients alive with-
out recurrence, DFS was determined from the date of sur-
gery to the date of last news or trial endpoint. The distinction 
between the recurrence of the original lung cancer and onset 
of a second primary lung cancer was based on the definition 
of Martini and Melamed.24 At the endpoint date (December, 
31 2007 in trial I and December, 31 2008 in trial II), the 
physicians in charge were invited to contact patients to deter-
mine their vital status. oS and DFS rates along with SDs 
were estimated using the Kaplan–Meier method. Differences 
FIGURE 2. Trial II design.
FIGURE 3. Flow chart.
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in oS and DFS according to pathologic responses were 
tested for significance using the log-rank test. Unadjusted 
risk ratios along with their 95% confidence intervals (CI) 
were estimated by means of univariate Cox models, and used 
to describe the relationship between pCR and the main prog-
nostic factors with oS and DFS. Multivariate analyses using 
Cox models stratified by randomization arm were performed 
for oS and DFS to test the prognostic value of pCR after 
adjusting for other prognostic factors. All variables relating 
to oS and DFS with a p value less than or equal to 0.20 
in Cox univariate analysis were included in the multivariate 
analyses. Proportional hazard assumptions were examined 
for each Cox model variable using graphical methods or test-
ing an interaction term with time for significance.
Finally, predictive factors of pCR were identified 
using multivariable logistic regression, with pCR status as 
a dependant variable and baseline patient characteristics as 
independent variables. p values were two-sided, with values 
< 0.05 considered statistically significant. All analysis were 
performed using SAS 9.3 (SAS Institute, Cary, NC)
RESULTS
Patient Characteristics
In total, 492 patients were eligible for inclusion in the 
current analysis, comprising 91 trial-I patients (18.5%) and 
401 trial-II patients (81.5%) (Fig. 3). Pretreatment patient and 
tumor characteristics are summarized in Table 1. Median age at 
randomization was 61 years (range, 34–75 years). The majority 
of patients were men (83.9%), former or current smokers 
(94.3%) having a PS of 0 (77.0%) and stage-IB disease (60.0%). 
overall, there were 51.0% of squamous-cell–carcinoma 
TABLE 1. Patient Characteristics by Pathologic Response
Characteristics
Total
Pathologic Response
P
Incomplete Complete
No. (%) No. (%) No. (%)
Total 492 (100) 451 (91.7) 41 (8.3)
Age, years
 ≤70 445 (90.5) 406 (90.0) 39 (95.1) 0.409a
 >70 47 (9.5) 45 (10.0) 2 (4.9)
Sex
 Male 413 (83.9) 378 (83.8) 35 (85.4) 0.795b
 Female 79 (16.1) 73 (16.2) 6 (14.6)
Smoking status
 Non-smoker 28 (5.7) 28 (6.2) 0 (0.0) 0.188b
 Current Smoker 330 (67.1) 303 (67.2) 27 (65.8)
 Former smoker 134 (27.2) 120 (26.6) 14 (34.2)
Histology
 Non-squamous 241 (49.0) 233 (51.7) 8 (19.5) <0.0001b
 Squamous 251 (51.0) 218 (48.3) 33 (80.5)
WHo PS
 0 379 (77.0) 349 (77.4) 30 (73.2) 0.659a
 1 110 (22.4) 99 (21.9) 11 (26.8)
 2 3 (0.6) 3 (0.7) 0 (0.0)
Weight loss
 ≤5% 450 (91.5) 414 (91.8) 36 (87.8) 0.378a
 >5% 42 (8.5) 37 (8.2) 5 (12.2)
cT
 1 18 (3.7) 16 (3.5) 2 (4.9) 0.193a
 2 428 (87.0) 390 (86.5) 38 (92.7)
 3 46 (9.3) 45 (10.0) 1 (2.4)
cN 0.055b
 0 341 (69.3) 318 (70.5) 23 (56.1)
 1 151 (30.7) 133 (29.5) 18 (43.9)
Clinical stage
 IB 295 (60.0) 273 (60.5) 22 (53.6) 0.972b
 IIA 18 (3.6) 16 (3.6) 2 (4.9)
 IIB 179 (36.4) 162 (35.9) 17 (41.5)
ax-squared test.
bFisher’s exact test.
WHo, World Health organization; PS, performance status.
Bold indicates significance.
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(SCC) patients but the proportion of SCC was higher in trial-I 
patients (73.6% versus. 45.9% in trial II).
overall, 41 patients (8.3%) achieved pCR. The propor-
tion of SCC was significantly higher among pCR patients 
(80.5% versus 48.3% in non-pCR patients). Administered 
treatments according to pCR status are presented in Table 2. 
Between the pCR and non-pCR groups there were no statis-
tically significant differences regarding trials, chemotherapy 
regimens, and therapeutic strategies (preoperative or periop-
erative chemotherapy). All patients with pCR were consid-
ered to be clinically responders, with five (12.2%) patients 
achieving cCR and 36 (87.82%) cPR. In the non-pCR group, 
six (2.2%) patients were considered to have cCR. In the pCR 
group 87.8% of patients underwent lobectomy or bilobectomy 
versus 68.7% in the non-pCR group (p = 0.011).
Postoperative OS and Disease Free Survival
Vital status was available for 98% of patients at the 
trial closing date, with 10 patients lost to follow-up includ-
ing one pCR group patient after a delay of 5.5 years. Median 
follow-up was 5.6 years (range, 3.0–16.6 years). Comparison 
of Kaplan–Meier survival curves according to pathologic 
responses revealed significantly improved oS in pCR patients 
(Fig. 4). During follow-up, 10 (24.4%) patients died in the 
pCR group versus 217 (48.1%) in the non-pCR group, with 
5-year oS rates being 80.0% (±7.0) and 55.8% (±2.5), respec-
tively (log rank test, p = 0.0007). Median oS was not reached 
in the pCR group, whereas it was 69.6 months (95% CI = 
59.21–95.34) in the non-pCR group. In the pCR group, two 
patients died from the evolution of their primary tumor, one 
from intercurrent disease, two from treatment-related death, 
one from ear, nose, and throat cancer, and four from unknown 
reason. Treatment-related deaths included: one death from a 
pulmonary infection 7 days after bilobectomy and one death 
from a stroke 4 days after surgery. The intercurrent disease 
consisted of a stroke 12 years after surgery.
Table 3 shows unadjusted risk ratios for oS and DFS 
estimated using univariate analysis Cox models. Univariate 
analysis revealed pCR to reduce the risk of death by 65% 
(relative risk [RR] = 0.35; 95% CI = 0.18–0.66). In univari-
ate analysis, other significant factors were histological type 
(RR = 0.65; 95% CI = 0.50–0.84 for SCC compared to 
non-SCC) and weight loss more than 5% (RR = 1.59; 95% 
CI = 1.06–2.37).
Multivariate Cox regression models showed that pCR 
significantly reduced the risk of death (RR = 0.34; 95% CI 
= 0.18–0.64) as did squamous-cell histological type (RR = 
0.66; 95% CI = 0.50–0.87) (Table 4). In contrast, weight loss 
more than 5% (RR = 1.64; 95% CI = 1.09–2.47) and stage-IIB 
disease (RR = 1.40; 95% CI = 1.06–1.84) were significantly 
related to a higher risk of death.
Furthermore, 5-year DFS was significantly improved in 
patients with pCR compared with non-pCR patients (80.1% 
± 7.1% versus 44.8% ± 2.5%, respectively; log-rank test, p < 
0.0001). The only other variable significantly associated with 
improved DFS in univariate analysis was SCC (RR = 0.55; 
95% CI = 0.43–0.71 for SCC compared to non-SCC) (Table 
3). Multivariate analysis using Cox regression models showed 
a favorable effect of pCR (RR = 0.29; 95% CI = 0.16–0.56), 
SCC (RR = 0.56; 95% CI = 0.44–0.73) on DFS, whereas 
stage-IIB disease compared to stage-IB disease (RR = 1.41; 
95% CI = 1.09–1.81) was significantly related to poorer DFS 
(Table 4).
TABLE 2. Patient Treatments by Pathologic Response
Characteristics
Total
Pathologic response
pa
Incomplete Complete
No. (%) No. (%) No. (%)
Total 492 (100) 451 (91.7) 41 (8.3)
Trial
 Trial I 91 (18.5) 80 (17.7) 11 (26.8) 0.151
 Trial II 401 (81.5) 371 (82.3) 30 (73.2)
Randomization arm
 MIC PERI 91 (18.5) 80 (17.8) 11 (26.8) 0.159
 GP PRE 106 (21.6) 100 (22.2) 6 (14.6)
 GP PERI 97 (19.7) 89 (19.7) 8 (19.5)
 CT PRE 101 (20.5) 89 (19.7) 12 (29.3)
 CT PERI 97 (19.7) 93 (20.6) 4 (9.8)
Chemotherapy strategy
 PRE 207 (42.1) 189 (41.9) 18 (43.9) 0.804
 PERI 285 (57.9) 262 (58.1) 23 (56.1)
Type of surgery
 Lobectomy/Bilobectomy 346 (70.3) 310 (68.7) 36 (87.8) 0.011
 Pneumonectomy 146 (29.7) 141 (31.3) 5 (12.2)
ax-squared test
MIC, mitomycin–ifosfamide–cisplatin; GP, gemcitabine–cisplatin; CT, carboplatin–placitaxel; PERI, 
perioperative; PRE, preoperative.
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Recurrences and Second Primary Cancers
Among the 492 patients, 195 (39.6%) experienced dis-
ease recurrence. However, recurrence occurred in only two 
pCR patients (4.9%) compared with 193 non-pCR patients 
(42.8%). In the non-pCR group, 131 recurrences (67.9%) were 
considered distant. The most common sites of recurrence were 
the brain (24.1%), lung (17.4%), and mediastinum (15.4%). 
Regarding the two cases of disease recurrence in the pCR 
group, one involved a trial-I patient who was male, former 
smoker, aged 69 years, with PS 0, and weight loss less than 
5%. The patient was diagnosed with cT2N0M0 SCC, achieved 
cPR after two cycles of MIC regimen, and underwent surgical 
lobectomy. The histologically proven recurrence occurred in 
the trachea, carina, and left main bronchus 17 months after 
surgery. The other pCR patient experiencing a recurrence was 
treated for a cT2N0M0 large-cell carcinoma in trial II, having 
undergone four cycles of CP before lobectomy. This patient 
was a 47-year-old female, with PS 0 and weight loss less than 
5%. She achieved cPR after preoperative chemotherapy, with 
multiple lung metastases occurring 27 months after surgery. 
FIGURE 4. Kaplan–Meier survival plots according to patho-
logic response: (A) Overall survival (B) Disease-free survival. 
*Log-rank test.
TABLE 3. Unadjusted Risk Ratios (univariate Cox model) 
for Postoperative Overall and Disease-Free Survival by 
Patient Characteristics at Baseline
Characteristics No.
Overall survival Disease-free survival
RR 95% CI pa RR 95% CI pa
Age, yr 0.480 0.351
 ≤70 445 1 1
 >70 47 0.84 0.51–1.73 0.81 0.52–1.26
Sex 0.933 0.946
 Male 413 1 1
 Female 79 0.98 0.68–1.43 1.01 0.72–1.42
Smoking status 0.855 0.802
 Never smoker 28 1 1
 Smoker 464 1.06 0.58–1.94 0.94 0.56–1.58
Histology 0.001 <0.0001
 Non-squamous 241 1 1
 Squamous 251 0.65 0.50–0.84 0.55 0.43–0.71
WHo PS 0.913 0.595
 0 379 1 1
 ≥1 113 1.02 0.75–1.38 0.93 0.69–1.23
Weight loss 0.023 0.100
 ≤5% 450 1 1
 >5% 42 1.59 1.06–2.37 1.39 0.94–2.05
cT 0.011 0.073
 1 18 1 1
 2 428 0.99 0.47–2.12 1.12 0.55–2.26
 3 46 1.76 0.78–4.01 1.70 0.78–3.69
cN 0.736 0.865
 0 341 1 1
 1 151 0.95 0.71–1.27 1.02 0.79–1.33
Clinical Stage 0.338 0.257
 IB 295 1 1
 IIA 18 1.02 0.48–2.18 0.93 0.45–1.89
 IIB 179 1.22 0.93–1.60 1.22 0.95–1.57
Trial 0.785 0.721
 Trial I 91 1 1
 Trial II 401 0.96 0.69–1.33 1.09 0.80–1.48
Randomization  
arm
0.587 0.946
 MIC PERI 91 1 1
 GP PRE 106 0.86 0.56–1.32 1.08 0.73–1.59
 GP PERI 97 0.97 0.64–1.48 1.05 0.71–1.57
 CT PRE 101 1.15 0.77–1.72 1.17 0.80–1.73
 CT PERI 97 0.83 0.53–1.30 1.03 0.69–1.55
Chemotherapy  
strategy
0.645 0.497
 PRE 207 1 1
 PERI 285 0.94 0.71–0.12 0.92 0.71–1.18
pCR 0.0007 <0.0001
 No 451 1 1
 Yes 41 0.35 0.18–0.66 0.28 0.15–0.53
aScore test.
Bold indicates significance.
RR, relative risk; pCR, pathologic complete response; MIC, mitomycin–ifosfamide–
cisplatin; GP, gemcitabine–cisplatin; CT, carboplatin–placitaxel; PERI, perioperative; 
PRE, preoperative; CI, confidence interval.
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She continued to smoke throughout the disease. Both patients 
died from NSCLC.
During follow-up, six pCR patients (14.6%) experi-
enced a second primary cancer (two NSCLC, three ENT can-
cers, and one prostate cancer) versus 47 patients (10.4%) in 
the non-pCR group (16 NSCLC, 11 colorectal cancers, seven 
prostate cancers, and 19 other-site cancers).
Predictive Factors of pCR
In univariate analysis, only the histological type was sig-
nificantly related to pCR, with a significantly higher propor-
tion of pCR among SCC patients (Table 1). The  histological 
type was the only independent predictive factor of pCR in 
multivariate analyses, with SCC patients being more likely to 
achieve pCR (oR = 4.30; 95% CI = 1.90–9.72; p < 0.0005). 
Whereas randomization arm and stage were not correlated 
with the occurrence of pCR.
DISCUSSION
our study revealed 5-year postoperative oS and DFS 
rates of 80.0% in pCR patients versus 55.8% and 44.8%, 
respectively in non-pCR patients, demonstrating that pCR 
after neoadjuvant chemotherapy was a strong, favorable prog-
nostic factor of oS (RR = 0.34; 95% CI = 0.18–0.64) and 
DFS (RR = 0.29; 95% CI = 0.16–0.56). To our knowledge, 
our study included the largest series of pCR after preopera-
tive chemotherapy for NSCLC patients (n = 41), published to 
date. The 73 stage-IIIA patients of trial I and the 89 stage-IA 
patients of trial II were not included in the present analysis, 
with the aim of a homogeneous population.
In the other phase-III trials evaluating neoadjuvant che-
motherapy, the rate of pCR ranged from 3.7% (one patient)17 
to 10.5% (19 patients)18. Given the small pCR patient samples, 
few conclusions may be drawn from these studies with respect 
to patient outcome. Nonetheless, the phase-III study by Felip 
et al.18 evaluated 5-year DFS rates in pCR patients treated with 
preoperative CP for stage-IA (tumor size > 2 cm), -IB, -II, or 
-T3N1 NSCLC. In this report, DFS was estimated at 59% in 
the 19 pCR patients compared to 38.3% in the entire preopera-
tive chemotherapy group. Pisters et al.13 reported the outcome 
of a hospital series of 21 pCR patients following preoperative 
chemotherapy with mitomycin, vinca alkaloid, and cisplatin 
for stage-IIIA NSCLC between 1983 and 1992. The 5-year 
survival rate of 54% was significantly higher than that of a 
series of 35 non-pCR patients undergoing complete resection 
for stage-IIIA N2 NSCLC after preoperative chemotherapy 
(5-year survival = 15%) in the same institution. In a phase-II 
study involving 34 patients, Elias et al.15 reported a recurrence 
in two out of six pCR patients compared to four out of six 
non-pCR patients with mediastinal nodal clearance follow-
ing cisplatin, 5-fluorouracil, and leucovorin chemotherapy 
for stage-IIIA N2 NSCLC. In a phase-II trial investigating 
the efficacy of neoadjuvant docetaxel-cisplatin in stage-IIIA 
N2 NSCLC patients, the Swiss Group for Clinical Cancer 
Research reported a total of 13 pCR among 75 patients under-
going tumor resection after three cycles of chemotherapy.11 
However, contrary to the trials cited above and our own study, 
pCR was defined as necrosis more than or equal to 95% and 
fibrosis at pathologic examination. Consequently, patients with 
a small number of persistent viable tumor cells were consid-
ered pCR patients. In univariate analysis, pCR was found to be 
predictive of improved oS and event-free survival, decreased 
risk of local relapse, and distant metastases. Although our 
study findings confirm this improved outcome in cases of pCR 
after preoperative chemotherapy, it must be stressed that our 
analysis was based on a larger and homogeneous sample of 41 
early-stage NSCLC patients, who were prospectively assessed 
in two multicenter randomized phase-III trials, with pCR 
strictly defined as the absence of cancer cells in the surgically 
resected specimens.
Among our 41 pCR patients, only two experienced dis-
ease recurrence, with loco-regional metastases observed in 
TABLE 4. Adjusted Risk Ratios (Multivariate Cox Analysis)a for Postoperative Overall and Disease-Free Survival
Characteristics
Overall Survival Disease-free survival
RR 95% CI pb RR 95% CI pb
pCR
 No 1 1
 Yes 0.34 0.18–0.64 0.0009 0.29 0.16–0.56 0.0002
Histology
 Non-squamous 1 1
 Squamous 0.66 0.50–0.87 0.003 0.56 0.44–0.73 <0.0001
Weight Loss
 ≤5% 1 1
 >5% 1.64 1.09–2.47 0.017 1.47 0.99–2.19 0.057
Clinical Stage
 IB 1 1
 IIA 1.19 0.55–2.60 0.654 1.00 0.49–2.06 0.999
 IIB 1.40 1.06–1.84 0.019 1.41 1.09–1.81 0.009
aStratified by randomization arm.
bWald Test.
RR, relative risk; CI, confidence interval; pCR, pathologic complete response.
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one patient and multiple lung metastases in the other. Pisters 
et al.13 reported eight patients experiencing disease recurrence, 
mainly brain metastases (n = 5), from a series of 21 pCR fol-
lowing neoadjuvant chemotherapy for stage-III NSCLC. In a 
retrospective analysis reported by Chen et al.25 211 patients 
were treated with neoadjuvant chemotherapy or chemoradio-
therapy for stage-IIIA or -IIIB NSCLC, with 51 pCRs being 
observed, 29 after chemotherapy and 22 after chemoradiation. 
Disease recurrence occurred in 31 patients with the first site 
of recurrence being the brain in 22 patients. In these published 
series, the more advanced disease was likely to account for the 
higher risk of recurrence despite pCR, and for the high rate of 
brain metastases. In the study of Chen et al.25 the combination 
of chemotherapy and radiotherapy may have contributed in 
reducing the loco-regional risk of recurrence. Given the small 
number of recurrences observed in our study, we are not able 
to determine whether there is a preferential site of relapse for 
stage-IB and -II NSCLC in pCR patients following neoadju-
vant chemotherapy. Previous results strongly suggested that 
neoadjuvant chemotherapy decreases the risk of metastases.9 
In case of pCR after neoadjuvant chemotherapy for early-stage 
NSCLC, the risk of recurrence is very low, with most patients 
achieving disease cure.
As pCR seems to be a predictor of cure, the selection of 
patients who may achieve a complete response is of clinical 
interest. Several models were tested in our study, including ran-
domization arm or trial, as well as cT and cN status or clinical 
stage. The results based on these models were similar, revealing 
that SCC was the only and strongly independent prognostic fac-
tor of pCR (oR = 4.30; 95% CI = 1.90–9.72). Among the 492 
patients, 251 patients (51%) were diagnosed with SCC. Triplet-
combination chemotherapy was shown to increase response 
rates in advanced disease.26 The proportion of SCC was higher 
in trial I (73.6% versus 45.9% in trial II), which used a trip-
let regimen. However, no interaction between histological type 
and trial was shown in multivariate analyses. Therefore, the 
use of a three-drug combination is unlikely to account for the 
higher proportion of complete responders among SCC patients. 
Another explanation may be the use of the cisplatin-gemcit-
abine combination, because gemcitabine was reported to be 
associated with improved survival as compared to pemetrexed 
in SCC patients with advanced NSCLC.27,28 However, in trial II, 
14 patients experienced pCR after cisplatin–gemcitabine com-
pared to 16 patients after paclitaxel–carboplatin. In advanced 
NSCLC, SCC was rarely reported to be more sensitive to che-
motherapy than the other histological types.29,30 Indeed, adeno-
carcinoma was shown to be more frequently associated with 
increased response rates.31 Nevertheless, extrapolating findings 
observed in cases of advanced NSCLC may not be the best 
approach to explain results achieved in patients with more lim-
ited disease.32,33 Studies using molecular predictive markers of 
response would probably be more valuable.
Among the 11 clinical complete responders, six experi-
enced pCR. All patients with pCR were clinically considered to be 
responders, either complete (n = 5) or partial responders (n = 36). 
our results confirm the previously reported findings, which were 
based solely on trial I data, showing that cCR was predictive of 
pCR, and that CT assessments likely underestimated pCR rates.34
To conclude, our results revealed that pCR after preoper-
ative chemotherapy was a robust favorable prognostic factor in 
clinical stage-IB and -II NSCLC. our study involved the largest 
series of pCRs after preoperative chemotherapy, published to 
date. The only predictive factor of pCR was SCC. In operable 
NSCLC, as in more advanced diseases, treatment personaliza-
tion may lead to improved results. Identifying molecular predic-
tive markers for pCR may help in distinguishing patients who 
may benefit from neoadjuvant chemotherapy, and in choosing 
the most adequate preoperative chemotherapy regimen.
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